Camerini A - Search Results

1

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R. Del Re M, et al. Among authors: camerini a. Oncotarget. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957. Oncotarget. 2017. PMID: 26799287 Free PMC article.

2

Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis.

Sgambato A, Zannoni GF, Faraglia B, Camerini A, Tarquini E, Spada D, Cittadini A. Sgambato A, et al. Among authors: camerini a. Gynecol Oncol. 2004 Mar;92(3):776-83. doi: 10.1016/j.ygyno.2003.12.008. Gynecol Oncol. 2004. PMID: 14984940

3

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A. Sgambato A, et al. Among authors: camerini a. J Cell Physiol. 2004 Oct;201(1):97-105. doi: 10.1002/jcp.20045. J Cell Physiol. 2004. PMID: 15281092

4

Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine-2 treatment.

Camerini A, Tartarelli G, Martini L, Donati S, Puccinelli P, Amoroso D. Camerini A, et al. Int J Urol. 2007 Mar;14(3):259-60. doi: 10.1111/j.1442-2042.2007.01674.x. Int J Urol. 2007. PMID: 17430270

5

Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma.

Sgambato A, Camerini A, Amoroso D, Genovese G, De Luca F, Cecchi M, Migaldi M, Rettino A, Valsuani C, Tartarelli G, Donati S, Siclari O, Rossi G, Cittadini A. Sgambato A, et al. Among authors: camerini a. Cancer Biol Ther. 2007 Dec;6(12):1840-6. doi: 10.4161/cbt.6.12.4983. Epub 2007 Sep 5. Cancer Biol Ther. 2007. PMID: 18087214 Free article.

6

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.

Camerini A, Rondini M, Garrone O, Valsuani C, Donati S, Siclari O, Sgambato A, Tartarelli G, Vincenti M, Mattiot VP, Porta RP, Puccetti C, Puccinelli P, Amoroso D. Camerini A, et al. Cancer Biol Ther. 2009 Aug;8(15):1450-5. doi: 10.4161/cbt.8.15.8959. Epub 2009 Aug 8. Cancer Biol Ther. 2009. PMID: 19556864 Free article. Clinical Trial.

7

Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.

Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati S, Rondini M, Tartarelli G, Puccinelli P, Di Costanzo F, Amoroso D. Camerini A, et al. Ann Oncol. 2010 Jun;21(6):1290-1295. doi: 10.1093/annonc/mdp525. Epub 2009 Nov 13. Ann Oncol. 2010. PMID: 19914959 Free article. Clinical Trial.

8

Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.

Camerini A, Donati S, Viacava P, Siclari O, Puccetti C, Tartarelli G, Valsuani C, De Luca F, Martini L, Cavazzana A, Amoroso D. Camerini A, et al. J Exp Clin Cancer Res. 2011 Apr 11;30(1):38. doi: 10.1186/1756-9966-30-38. J Exp Clin Cancer Res. 2011. PMID: 21481270 Free PMC article.

9

First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.

Tibaldi C, Camerini A, D'Incecco A, Vasile E, Fabbri A, Amoroso D, Cappuzzo F. Tibaldi C, et al. Among authors: camerini a. J Cancer Res Clin Oncol. 2012 Dec;138(12):2003-8. doi: 10.1007/s00432-012-1280-5. Epub 2012 Jul 6. J Cancer Res Clin Oncol. 2012. PMID: 22767317 Clinical Trial.

10

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A. Tiseo M, et al. Among authors: camerini a. Lung Cancer. 2012 Oct;78(1):92-9. doi: 10.1016/j.lungcan.2012.07.009. Epub 2012 Aug 11. Lung Cancer. 2012. PMID: 22889494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters